English

CODIAK BIOSCIENCES, INC.

EDGAR

CDAK Quarterly report (10-Q) · filed 2022-11-03

15 filing records in this dataset, filed from 2019-04-29 to 2022-11-03. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

522 thousand USD

2022 Q3 · USD

Exact inputs and evidence

Revenue: 522000 USD Source

Operating margin

-4,098.85%

2022 Q3 · %

Exact inputs and evidence

Operating Income: -21396000 USD Source
Revenue: 522000 USD Source

Operating cash flow

-10.1 million USD

2022 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: -45558000 USD Source
Operating Cash Flow: -35448000 USD Source

Free cash flow

-10.1 million USD

2022 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: -45558000 USD Source
Operating Cash Flow: -35448000 USD Source
Capital Expenditure: 362000 USD Source
Capital Expenditure: 353000 USD Source

Cash and cash equivalents: 51.8 million USD 2022-09-30 Source
Exact value

51762000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 36.8 million shares 2022-09-30 Source
Exact value

36829626 shares

Reported share-count change

64.70% · 14.5 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

22361305 shares · 2021-09-30· Source
36829626 shares · 2022-09-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

34.1 million USD

2021-10-01 – 2022-09-30

Exact inputs and evidence

Revenue: 22935000 USD · 2021-01-01 – 2021-12-31 Source
Revenue: 15238000 USD · 2021-01-01 – 2021-09-30 Source
Revenue: 12704000 USD · 2022-01-01 – 2022-03-31 Source
Revenue: 13145000 USD · 2022-04-01 – 2022-06-30 Source
Revenue: 522000 USD · 2022-07-01 – 2022-09-30 Source

Net income

-17.4 million USD

2021-10-01 – 2022-09-30

Exact inputs and evidence

Net income: -37157000 USD · 2021-01-01 – 2021-12-31 Source
Net income: -53819000 USD · 2021-01-01 – 2021-09-30 Source
Net income: -8028000 USD · 2022-01-01 – 2022-03-31 Source
Net income: -6775000 USD · 2022-04-01 – 2022-06-30 Source
Net income: -19278000 USD · 2022-07-01 – 2022-09-30 Source

Operating cash flow

-67.1 million USD

2021-10-01 – 2022-09-30

Exact inputs and evidence

Operating cash flow: -74144000 USD · 2021-01-01 – 2021-12-31 Source
Operating cash flow: -52622000 USD · 2021-01-01 – 2021-09-30 Source
Operating cash flow: -20851000 USD · 2022-01-01 – 2022-03-31 Source
Operating cash flow: -35448000 USD · 2022-01-01 – 2022-06-30 Source
Operating cash flow: -20851000 USD · 2022-01-01 – 2022-03-31 Source
Operating cash flow: -45558000 USD · 2022-01-01 – 2022-09-30 Source
Operating cash flow: -35448000 USD · 2022-01-01 – 2022-06-30 Source

Capital expenditure

694 thousand USD

2021-10-01 – 2022-09-30

Exact inputs and evidence

Capital expenditure: 3245000 USD · 2021-01-01 – 2021-12-31 Source
Capital expenditure: 2913000 USD · 2021-01-01 – 2021-09-30 Source
Capital expenditure: 182000 USD · 2022-01-01 – 2022-03-31 Source
Capital expenditure: 353000 USD · 2022-01-01 – 2022-06-30 Source
Capital expenditure: 182000 USD · 2022-01-01 – 2022-03-31 Source
Capital expenditure: 362000 USD · 2022-01-01 – 2022-09-30 Source
Capital expenditure: 353000 USD · 2022-01-01 – 2022-06-30 Source

Free cash flow

-67.8 million USD

2021-10-01 – 2022-09-30

Exact inputs and evidence

Operating cash flow: -74144000 USD · 2021-01-01 – 2021-12-31 Source
Operating cash flow: -52622000 USD · 2021-01-01 – 2021-09-30 Source
Operating cash flow: -20851000 USD · 2022-01-01 – 2022-03-31 Source
Operating cash flow: -35448000 USD · 2022-01-01 – 2022-06-30 Source
Operating cash flow: -20851000 USD · 2022-01-01 – 2022-03-31 Source
Operating cash flow: -45558000 USD · 2022-01-01 – 2022-09-30 Source
Operating cash flow: -35448000 USD · 2022-01-01 – 2022-06-30 Source
Capital expenditure: 3245000 USD · 2021-01-01 – 2021-12-31 Source
Capital expenditure: 2913000 USD · 2021-01-01 – 2021-09-30 Source
Capital expenditure: 182000 USD · 2022-01-01 – 2022-03-31 Source
Capital expenditure: 353000 USD · 2022-01-01 – 2022-06-30 Source
Capital expenditure: 182000 USD · 2022-01-01 – 2022-03-31 Source
Capital expenditure: 362000 USD · 2022-01-01 – 2022-09-30 Source
Capital expenditure: 353000 USD · 2022-01-01 – 2022-06-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2022-11-03.

Financial data available through: 2021-12-31.

Coverage by financial measure

Revenue: 3 of 11 periods available· newest 2021-12-31
Operating income: 4 of 11 periods available· newest 2021-12-31
Net income: 4 of 11 periods available· newest 2021-12-31
Operating cash flow: 4 of 11 periods available· newest 2021-12-31
Capital expenditure: 4 of 11 periods available· newest 2021-12-31
Total assets: 3 of 11 periods available· newest 2021-12-31
Total liabilities: 3 of 11 periods available· newest 2021-12-31
Current assets: 3 of 11 periods available· newest 2021-12-31
Current liabilities: 3 of 11 periods available· newest 2021-12-31
Cash and cash equivalents: 3 of 11 periods available· newest 2021-12-31
long term debt: No compatible figures in this window
Shares outstanding: 3 of 11 periods available· newest 2021-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+686.8%

Prior period

USD 2.92 million

2020-01-01 – 2020-12-31
Current period

USD 22.94 million

2021-01-01 – 2021-12-31

Exact inputs and evidence

22935000 − 2915000 = 20020000 USD

2915000 USD · 2020-01-01 – 2020-12-31
Inspect prior input Prior source
22935000 USD · 2021-01-01 – 2021-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · CODIAK BIOSCIENCES, INC. · 2021-12-31 CODIAK BIOSCIENCES, INC. (edgar:1659352) Year-over-year change in Revenue: 20020000 USD Concept: fundies:Revenue Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T17:47:54Z Snapshot: 0b9cf8ca334c48e47b42d45abd2726f1deb0f1b6c05b2a750551eea3b8808a61 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659352?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 22935000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659352/000095017022003373/cdak-20211231.htm#3684034 Filing: 000095017022003373 Input fundies:Revenue: 2915000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659352/000095017022003373/cdak-20211231.htm#3685985 Filing: 000095017022003373
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 54.51 million

Prior period

−USD 91.67 million

2020-01-01 – 2020-12-31
Current period

−USD 37.16 million

2021-01-01 – 2021-12-31

Exact inputs and evidence

-37157000 − -91665000 = 54508000 USD

-91665000 USD · 2020-01-01 – 2020-12-31
Inspect prior input Prior source
-37157000 USD · 2021-01-01 – 2021-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · CODIAK BIOSCIENCES, INC. · 2021-12-31 CODIAK BIOSCIENCES, INC. (edgar:1659352) Year-over-year change in Net income: 54508000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T17:47:54Z Snapshot: 0b9cf8ca334c48e47b42d45abd2726f1deb0f1b6c05b2a750551eea3b8808a61 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659352?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -37157000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659352/000095017022003373/cdak-20211231.htm#3966596 Filing: 000095017022003373 Input fundies:NetIncome: -91665000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659352/000095017022003373/cdak-20211231.htm#3968573 Filing: 000095017022003373
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 10.78 million

Prior period

−USD 63.36 million

2020-01-01 – 2020-12-31
Current period

−USD 74.14 million

2021-01-01 – 2021-12-31

Exact inputs and evidence

-74144000 − -63361000 = -10783000 USD

-63361000 USD · 2020-01-01 – 2020-12-31
Inspect prior input Prior source
-74144000 USD · 2021-01-01 – 2021-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · CODIAK BIOSCIENCES, INC. · 2021-12-31 CODIAK BIOSCIENCES, INC. (edgar:1659352) Year-over-year change in Operating cash flow: -10783000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T17:47:54Z Snapshot: 0b9cf8ca334c48e47b42d45abd2726f1deb0f1b6c05b2a750551eea3b8808a61 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659352?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -74144000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659352/000095017022003373/cdak-20211231.htm#2784252 Filing: 000095017022003373 Input fundies:OperatingCashFlow: -63361000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659352/000095017022003373/cdak-20211231.htm#2786168 Filing: 000095017022003373
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-84.6%

Prior period

USD 21.05 million

2020-01-01 – 2020-12-31
Current period

USD 3.25 million

2021-01-01 – 2021-12-31

Exact inputs and evidence

3245000 − 21052000 = -17807000 USD

21052000 USD · 2020-01-01 – 2020-12-31
Inspect prior input Prior source
3245000 USD · 2021-01-01 – 2021-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · CODIAK BIOSCIENCES, INC. · 2021-12-31 CODIAK BIOSCIENCES, INC. (edgar:1659352) Year-over-year change in Capital expenditure: -17807000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T17:47:54Z Snapshot: 0b9cf8ca334c48e47b42d45abd2726f1deb0f1b6c05b2a750551eea3b8808a61 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659352?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 3245000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659352/000095017022003373/cdak-20211231.htm#2791128 Filing: 000095017022003373 Input fundies:CapitalExpenditure: 21052000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659352/000095017022003373/cdak-20211231.htm#2793034 Filing: 000095017022003373
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2021 2021-01-01 – 2021-12-31

Revenue USD 22.94 million 100% of revenue
Operating costs Derived USD 92.48 million 403% of revenue
Operating income −USD 69.55 million −303% of revenue
Tax, interest and other Derived −USD 32.39 million −141% of revenue
Net income −USD 37.16 million −162% of revenue

Cash

Operating cash flow −USD 74.14 million −323% of revenue
Capital expenditure USD 3.25 million 14% of revenue
Free cash flow Derived −USD 77.39 million −337% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2019 Operating loss: operating costs were 20,758% of revenue.
2020 Operating loss: operating costs were 3,219% of revenue.
2021 Operating loss: operating costs were 403% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2019 2019-01-01 – 2019-12-31	388000	80540000 Derived	-80152000	-2192000 Derived	-77960000	-12179000 Derived	Source 2019-01-01 – 2019-12-31: 388000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -80152000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -77960000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -1703000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 10476000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	2915000	93833000 Derived	-90918000	747000 Derived	-91665000	-84413000 Derived	Source 2020-01-01 – 2020-12-31: 2915000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -90918000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -91665000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -63361000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 21052000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	22935000	92484000 Derived	-69549000	-32392000 Derived	-37157000	-77389000 Derived	Source 2021-01-01 – 2021-12-31: 22935000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -69549000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -37157000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -74144000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 3245000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 22.9M 2021

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20192019-12-31	Revenue	388000	Revenue: 388000 Open source
20202020-12-31	Revenue	2915000	Revenue: 2915000 Open source
20212021-12-31	Revenue	22935000	Revenue: 22935000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

686.8% 2021

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Year over year	No prior comparable period	Revenue: 388000 Open source
20202020-12-31	Year over year	651.3%	Revenue: 2915000 Open source Revenue: 388000 Open source
20212021-12-31	Year over year	686.8%	Revenue: 22935000 Open source Revenue: 2915000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -303.2% 2021

Net margin -162% 2021

Free cash flow margin -337.4% 2021

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Operating margin	-20,657.7%	Operating Income: -80152000 Open source Revenue: 388000 Open source
20202020-12-31	Operating margin	-3,119%	Operating Income: -90918000 Open source Revenue: 2915000 Open source
20212021-12-31	Operating margin	-303.2%	Operating Income: -69549000 Open source Revenue: 22935000 Open source
20192019-12-31	Net margin	-20,092.8%	Net Income: -77960000 Open source Revenue: 388000 Open source
20202020-12-31	Net margin	-3,144.6%	Net Income: -91665000 Open source Revenue: 2915000 Open source
20212021-12-31	Net margin	-162%	Net Income: -37157000 Open source Revenue: 22935000 Open source
20192019-12-31	Free cash flow margin	-3,138.9%	Revenue: 388000 Open source Operating Cash Flow: -1703000 Open source Capital Expenditure: 10476000 Open source
20202020-12-31	Free cash flow margin	-2,895.8%	Revenue: 2915000 Open source Operating Cash Flow: -63361000 Open source Capital Expenditure: 21052000 Open source
20212021-12-31	Free cash flow margin	-337.4%	Revenue: 22935000 Open source Operating Cash Flow: -74144000 Open source Capital Expenditure: 3245000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -74.1M 2021

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20192019-12-31	Operating cash flow	-1703000	Operating Cash Flow: -1703000 Open source
20202020-12-31	Operating cash flow	-63361000	Operating Cash Flow: -63361000 Open source
20212021-12-31	Operating cash flow	-74144000	Operating Cash Flow: -74144000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -77.4M 2021

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20192019-12-31	Free cash flow	-12179000	Operating Cash Flow: -1703000 Open source Capital Expenditure: 10476000 Open source
20202020-12-31	Free cash flow	-84413000	Operating Cash Flow: -63361000 Open source Capital Expenditure: 21052000 Open source
20212021-12-31	Free cash flow	-77389000	Operating Cash Flow: -74144000 Open source Capital Expenditure: 3245000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

68.8% 2021

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Liabilities / assets	81.1%	Total Liabilities: 94011000 Open source Total Assets: 115962000 Open source
20202020-12-31	Liabilities / assets	90.4%	Total Liabilities: 136774000 Open source Total Assets: 151341000 Open source
20212021-12-31	Liabilities / assets	68.8%	Total Liabilities: 118165000 Open source Total Assets: 171670000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

3.32× 2021

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Current assets / current liabilities	4.76×	Current Assets: 94118000 Open source Current Liabilities: 19755000 Open source
20202020-12-31	Current assets / current liabilities	5.31×	Current Assets: 93758000 Open source Current Liabilities: 17651000 Open source
20212021-12-31	Current assets / current liabilities	3.32×	Current Assets: 90171000 Open source Current Liabilities: 27165000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2018 2018-01-01 – 2018-12-31	−USD 44.54 million Exact value Exact value: -44542000 USD 2018-01-01 – 2018-12-31: -44542000 USD Inspect Net Income Open source Share or cite Citation for Net Income · CODIAK BIOSCIENCES, INC. · 2018-12-31 CODIAK BIOSCIENCES, INC. (edgar:1659352) Net Income: -44542000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T17:47:54Z Snapshot: 0b9cf8ca334c48e47b42d45abd2726f1deb0f1b6c05b2a750551eea3b8808a61 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659352/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -44542000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659352/000119312521034327/cdak-20200930.xml#1188686 Filing: 000119312521034327 The citation records this snapshot. The page link may show a newer release later.	−USD 30.57 million Exact value Exact value: -30573000 USD 2018-01-01 – 2018-12-31: -30573000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CODIAK BIOSCIENCES, INC. · 2018-12-31 CODIAK BIOSCIENCES, INC. (edgar:1659352) Operating Cash Flow: -30573000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T17:47:54Z Snapshot: 0b9cf8ca334c48e47b42d45abd2726f1deb0f1b6c05b2a750551eea3b8808a61 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659352/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -30573000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659352/000119312521034327/cdak-20200930.xml#1189642 Filing: 000119312521034327 The citation records this snapshot. The page link may show a newer release later.	USD 1.82 million Exact value Exact value: 1816000 USD 2018-01-01 – 2018-12-31: 1816000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CODIAK BIOSCIENCES, INC. · 2018-12-31 CODIAK BIOSCIENCES, INC. (edgar:1659352) Capital Expenditure: 1816000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T17:47:54Z Snapshot: 0b9cf8ca334c48e47b42d45abd2726f1deb0f1b6c05b2a750551eea3b8808a61 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659352/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1816000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659352/000119312521034327/cdak-20200930.xml#1200249 Filing: 000119312521034327 The citation records this snapshot. The page link may show a newer release later.	−USD 32.39 million Calculation and evidence -30573000 − 1816000 USD Exact free cash flow: -32389000 USD 2018-01-01 – 2018-12-31: -30573000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 1816000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CODIAK BIOSCIENCES, INC. · 2018-12-31 CODIAK BIOSCIENCES, INC. (edgar:1659352) Free cash flow: -32389000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T17:47:54Z Snapshot: 0b9cf8ca334c48e47b42d45abd2726f1deb0f1b6c05b2a750551eea3b8808a61 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659352?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -30573000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659352/000119312521034327/cdak-20200930.xml#1189642 Filing: 000119312521034327 Input fundies:CapitalExpenditure: 1816000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659352/000119312521034327/cdak-20200930.xml#1200249 Filing: 000119312521034327 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 77.96 million Exact value Exact value: -77960000 USD 2019-01-01 – 2019-12-31: -77960000 USD Inspect Net Income Open source Share or cite Citation for Net Income · CODIAK BIOSCIENCES, INC. · 2019-12-31 CODIAK BIOSCIENCES, INC. (edgar:1659352) Net Income: -77960000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T17:47:54Z Snapshot: 0b9cf8ca334c48e47b42d45abd2726f1deb0f1b6c05b2a750551eea3b8808a61 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659352/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -77960000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659352/000156459021013870/cdak-20201231.xml#211324 Filing: 000156459021013870 The citation records this snapshot. The page link may show a newer release later.	−USD 1.7 million Exact value Exact value: -1703000 USD 2019-01-01 – 2019-12-31: -1703000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CODIAK BIOSCIENCES, INC. · 2019-12-31 CODIAK BIOSCIENCES, INC. (edgar:1659352) Operating Cash Flow: -1703000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T17:47:54Z Snapshot: 0b9cf8ca334c48e47b42d45abd2726f1deb0f1b6c05b2a750551eea3b8808a61 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659352/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -1703000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659352/000156459021013870/cdak-20201231.xml#240730 Filing: 000156459021013870 The citation records this snapshot. The page link may show a newer release later.	USD 10.48 million Exact value Exact value: 10476000 USD 2019-01-01 – 2019-12-31: 10476000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CODIAK BIOSCIENCES, INC. · 2019-12-31 CODIAK BIOSCIENCES, INC. (edgar:1659352) Capital Expenditure: 10476000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T17:47:54Z Snapshot: 0b9cf8ca334c48e47b42d45abd2726f1deb0f1b6c05b2a750551eea3b8808a61 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659352/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 10476000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659352/000156459021013870/cdak-20201231.xml#241152 Filing: 000156459021013870 The citation records this snapshot. The page link may show a newer release later.	−USD 12.18 million Calculation and evidence -1703000 − 10476000 USD Exact free cash flow: -12179000 USD 2019-01-01 – 2019-12-31: -1703000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 10476000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CODIAK BIOSCIENCES, INC. · 2019-12-31 CODIAK BIOSCIENCES, INC. (edgar:1659352) Free cash flow: -12179000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T17:47:54Z Snapshot: 0b9cf8ca334c48e47b42d45abd2726f1deb0f1b6c05b2a750551eea3b8808a61 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659352?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -1703000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659352/000156459021013870/cdak-20201231.xml#240730 Filing: 000156459021013870 Input fundies:CapitalExpenditure: 10476000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659352/000156459021013870/cdak-20201231.xml#241152 Filing: 000156459021013870 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 91.67 million Exact value Exact value: -91665000 USD 2020-01-01 – 2020-12-31: -91665000 USD Inspect Net Income Open source Share or cite Citation for Net Income · CODIAK BIOSCIENCES, INC. · 2020-12-31 CODIAK BIOSCIENCES, INC. (edgar:1659352) Net Income: -91665000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T17:47:54Z Snapshot: 0b9cf8ca334c48e47b42d45abd2726f1deb0f1b6c05b2a750551eea3b8808a61 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659352/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -91665000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659352/000095017022003373/cdak-20211231.htm#3968573 Filing: 000095017022003373 The citation records this snapshot. The page link may show a newer release later.	−USD 63.36 million Exact value Exact value: -63361000 USD 2020-01-01 – 2020-12-31: -63361000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CODIAK BIOSCIENCES, INC. · 2020-12-31 CODIAK BIOSCIENCES, INC. (edgar:1659352) Operating Cash Flow: -63361000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T17:47:54Z Snapshot: 0b9cf8ca334c48e47b42d45abd2726f1deb0f1b6c05b2a750551eea3b8808a61 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659352/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -63361000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659352/000095017022003373/cdak-20211231.htm#2786168 Filing: 000095017022003373 The citation records this snapshot. The page link may show a newer release later.	USD 21.05 million Exact value Exact value: 21052000 USD 2020-01-01 – 2020-12-31: 21052000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CODIAK BIOSCIENCES, INC. · 2020-12-31 CODIAK BIOSCIENCES, INC. (edgar:1659352) Capital Expenditure: 21052000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T17:47:54Z Snapshot: 0b9cf8ca334c48e47b42d45abd2726f1deb0f1b6c05b2a750551eea3b8808a61 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659352/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 21052000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659352/000095017022003373/cdak-20211231.htm#2793034 Filing: 000095017022003373 The citation records this snapshot. The page link may show a newer release later.	−USD 84.41 million Calculation and evidence -63361000 − 21052000 USD Exact free cash flow: -84413000 USD 2020-01-01 – 2020-12-31: -63361000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 21052000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CODIAK BIOSCIENCES, INC. · 2020-12-31 CODIAK BIOSCIENCES, INC. (edgar:1659352) Free cash flow: -84413000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T17:47:54Z Snapshot: 0b9cf8ca334c48e47b42d45abd2726f1deb0f1b6c05b2a750551eea3b8808a61 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659352?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -63361000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659352/000095017022003373/cdak-20211231.htm#2786168 Filing: 000095017022003373 Input fundies:CapitalExpenditure: 21052000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659352/000095017022003373/cdak-20211231.htm#2793034 Filing: 000095017022003373 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 37.16 million Exact value Exact value: -37157000 USD 2021-01-01 – 2021-12-31: -37157000 USD Inspect Net Income Open source Share or cite Citation for Net Income · CODIAK BIOSCIENCES, INC. · 2021-12-31 CODIAK BIOSCIENCES, INC. (edgar:1659352) Net Income: -37157000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T17:47:54Z Snapshot: 0b9cf8ca334c48e47b42d45abd2726f1deb0f1b6c05b2a750551eea3b8808a61 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659352/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -37157000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659352/000095017022003373/cdak-20211231.htm#3966596 Filing: 000095017022003373 The citation records this snapshot. The page link may show a newer release later.	−USD 74.14 million Exact value Exact value: -74144000 USD 2021-01-01 – 2021-12-31: -74144000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CODIAK BIOSCIENCES, INC. · 2021-12-31 CODIAK BIOSCIENCES, INC. (edgar:1659352) Operating Cash Flow: -74144000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T17:47:54Z Snapshot: 0b9cf8ca334c48e47b42d45abd2726f1deb0f1b6c05b2a750551eea3b8808a61 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659352/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -74144000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659352/000095017022003373/cdak-20211231.htm#2784252 Filing: 000095017022003373 The citation records this snapshot. The page link may show a newer release later.	USD 3.25 million Exact value Exact value: 3245000 USD 2021-01-01 – 2021-12-31: 3245000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CODIAK BIOSCIENCES, INC. · 2021-12-31 CODIAK BIOSCIENCES, INC. (edgar:1659352) Capital Expenditure: 3245000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T17:47:54Z Snapshot: 0b9cf8ca334c48e47b42d45abd2726f1deb0f1b6c05b2a750551eea3b8808a61 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659352/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3245000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659352/000095017022003373/cdak-20211231.htm#2791128 Filing: 000095017022003373 The citation records this snapshot. The page link may show a newer release later.	−USD 77.39 million Calculation and evidence -74144000 − 3245000 USD Exact free cash flow: -77389000 USD 2021-01-01 – 2021-12-31: -74144000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 3245000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CODIAK BIOSCIENCES, INC. · 2021-12-31 CODIAK BIOSCIENCES, INC. (edgar:1659352) Free cash flow: -77389000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T17:47:54Z Snapshot: 0b9cf8ca334c48e47b42d45abd2726f1deb0f1b6c05b2a750551eea3b8808a61 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659352?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -74144000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659352/000095017022003373/cdak-20211231.htm#2784252 Filing: 000095017022003373 Input fundies:CapitalExpenditure: 3245000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659352/000095017022003373/cdak-20211231.htm#2791128 Filing: 000095017022003373 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

15 filings · 784 latest values · 784 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001659352, 1659352, CDAK, edgar:1659352

Also known as CODIAK BIOSCIENCES, INC., Codiak BioSciences, Inc.

CODIAK BIOSCIENCES, INC.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2021 2021-01-01 – 2021-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation